Trevi Therapeutics (NASDAQ:TRVI) Earns Buy Rating from D. Boral Capital

Trevi Therapeutics (NASDAQ:TRVI)‘s stock had its “buy” rating reiterated by equities research analysts at D. Boral Capital in a research report issued on Wednesday,Benzinga reports. They presently have a $21.00 price target on the stock. D. Boral Capital’s price target would indicate a potential upside of 220.12% from the company’s current price.

Other equities analysts have also issued reports about the stock. HC Wainwright lifted their target price on shares of Trevi Therapeutics from $7.50 to $12.50 and gave the company a “buy” rating in a report on Monday, March 10th. Needham & Company LLC cut their target price on shares of Trevi Therapeutics from $25.00 to $24.00 and set a “buy” rating for the company in a report on Wednesday. Oppenheimer lifted their target price on shares of Trevi Therapeutics from $12.00 to $20.00 and gave the company an “outperform” rating in a report on Tuesday, March 11th. Finally, Raymond James raised shares of Trevi Therapeutics from an “outperform” rating to a “strong-buy” rating and lifted their target price for the company from $9.00 to $29.00 in a report on Monday, March 10th. Seven equities research analysts have rated the stock with a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat, Trevi Therapeutics presently has an average rating of “Buy” and an average price target of $15.81.

Trevi Therapeutics Trading Up 0.3 %

Shares of NASDAQ TRVI opened at $6.56 on Wednesday. Trevi Therapeutics has a 12 month low of $2.30 and a 12 month high of $7.39. The company has a 50 day simple moving average of $4.44 and a two-hundred day simple moving average of $3.68. The stock has a market cap of $504.24 million, a price-to-earnings ratio of -14.91 and a beta of 0.90.

Trevi Therapeutics (NASDAQ:TRVI) last announced its quarterly earnings data on Tuesday, March 18th. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.12) by $0.01. Analysts forecast that Trevi Therapeutics will post -0.49 EPS for the current year.

Insider Activity at Trevi Therapeutics

In related news, insider Farrell Simon sold 81,313 shares of the company’s stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $6.75, for a total value of $548,862.75. Following the completion of the sale, the insider now owns 76,900 shares of the company’s stock, valued at approximately $519,075. This represents a 51.39 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. 24.37% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of TRVI. Point72 Asset Management L.P. purchased a new position in Trevi Therapeutics during the fourth quarter worth about $17,099,000. Frazier Life Sciences Management L.P. boosted its stake in shares of Trevi Therapeutics by 44.5% in the fourth quarter. Frazier Life Sciences Management L.P. now owns 10,664,774 shares of the company’s stock valued at $43,939,000 after purchasing an additional 3,283,684 shares during the period. Woodline Partners LP boosted its stake in shares of Trevi Therapeutics by 429.9% in the fourth quarter. Woodline Partners LP now owns 3,212,597 shares of the company’s stock valued at $13,236,000 after purchasing an additional 2,606,370 shares during the period. Adage Capital Partners GP L.L.C. purchased a new position in shares of Trevi Therapeutics in the fourth quarter valued at approximately $10,300,000. Finally, Acorn Capital Advisors LLC purchased a new position in shares of Trevi Therapeutics in the fourth quarter valued at approximately $8,244,000. Hedge funds and other institutional investors own 95.76% of the company’s stock.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.